HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC Wainwright also issued estimates for Stoke Therapeutics’ Q1 2025 earnings at ($0.53) EPS and Q2 2025 earnings at ($0.54) EPS.

STOK has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $8.33 on Wednesday. The company has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99. The company has a 50-day simple moving average of $9.49 and a 200 day simple moving average of $11.49. Stoke Therapeutics has a 52 week low of $5.80 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Sell-side analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Activity

In other news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new position in Stoke Therapeutics in the 3rd quarter valued at approximately $160,000. Charles Schwab Investment Management Inc. lifted its stake in Stoke Therapeutics by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock valued at $3,885,000 after purchasing an additional 26,870 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares during the last quarter. Checkpoint Capital L.P. bought a new position in Stoke Therapeutics in the 3rd quarter valued at approximately $1,936,000. Finally, RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.